Synonym
BAP-909; BAP 909; BAP909; Imrecoxib
IUPAC/Chemical Name
4-(4-(Methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1H-pyrrol-2(5H)-one
InChi Key
AXMZZGKKZDJGAZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H23NO3S/c1-4-13-22-14-19(16-9-11-18(12-10-16)26(3,24)25)20(21(22)23)17-7-5-15(2)6-8-17/h5-12H,4,13-14H2,1-3H3
SMILES Code
O=C1N(CCC)CC(C2=CC=C(S(=O)(C)=O)C=C2)=C1C3=CC=C(C)C=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
369.48
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wang DC, Wang LC, Wang LJ, Chen G, Zhao YX, Zhao ZF, Li YH. [Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice]. Zhonghua Zhong Liu Za Zhi. 2016 May 23;38(5):340-5. doi: 10.3760/cma.j.issn.0253-3766.2016.05.004. Chinese. PubMed PMID: 27188605.
2: Feng Z, Chu F, Guo Z, Sun P. Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. doi: 10.1016/j.bmcl.2009.02.090. Epub 2009 Feb 27. PubMed PMID: 19286379.
3: Xu H, Zhang Y, Sun Y, Zhang P, Chu F, Guo Z, Zhang H, Zhong D. Metabolism and excretion of imrecoxib in rat. Xenobiotica. 2006 May;36(5):441-55. PubMed PMID: 16854781.
4: Xu HY, Zhang P, Gong AS, Sun YM, Chu FM, Guo ZR, Zhong DF. Formation of 4'-carboxyl acid metabolite of imrecoxib by rat liver microsomes. Acta Pharmacol Sin. 2006 Apr;27(4):506-12. PubMed PMID: 16539853.
5: Xu HY, Xie ZY, Zhang P, Sun J, Chu FM, Guo ZR, Zhong DF. Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib. Acta Pharmacol Sin. 2006 Mar;27(3):372-80. PubMed PMID: 16490176.
6: Li Q, Huang HH, Dong Y, Zhong DF. [Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs]. Yao Xue Xue Bao. 2005 Oct;40(10):912-5. Chinese. PubMed PMID: 16408808.
7: Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004 Jul;25(7):927-31. PubMed PMID: 15210067.
